Giovanna Bergamini

Giovanna Bergamini

Auto-generated profile, based on publicly available information

Giovanna Bergamini

Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, 69117 Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2015 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DBDaniel P Bondeson
Daniel P Bondeson
AMAlina Mares
Alina Mares
ISIan E D Smith
Ian E D Smith
EKEunhwa Ko
Eunhwa Ko
SCSebastien Campos
Sebastien Campos
CCCraig M. Crews
Craig M. Crews

25 January 2004 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
TBTewis Bouwmeester
Tewis Bouwmeester
ABAngela Bauch
Angela Bauch
HRHeinz Ruffner
Heinz Ruffner
PAPierre-Olivier Angrand
Pierre-Olivier Angrand
GBGiovanna Bergamini
Giovanna Bergamini
GSGiulio Superti-Furga
Giulio Superti-Furga

23 January 2011 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MBMarcus Bantscheff
Marcus Bantscheff
CHCarsten Hopf
Carsten Hopf
MSMikhail M Savitski
Mikhail M Savitski
ADAntje Dittmann
Antje Dittmann
PGPaola Grandi
Paola Grandi
GDGerard Drewes
Gerard Drewes

15 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMToby Mathieson
Toby Mathieson
HFHolger Franken
Holger Franken
JKJan Kosinski
Jan Kosinski
NKNils Kurzawa
Nils Kurzawa
NZNico Zinn
Nico Zinn
MSMikhail M. Savitski
Mikhail M. Savitski
A better understanding of proteostasis in health and disease requires robust methods to determine protein half-lives. Here we improve the precision and accuracy of peptide ion intensity-based quantification, enabling more accurate protein turnover determination in non-dividing cells by dynamic SILAC-based proteomics. This approach allows exact determination of protein half-lives ranging from 10 to >1000 h. We identified 4000–6000 proteins in several non-dividing cell types, corresponding to 9699 unique protein identifications over the entire data set. We observed similar protein half-lives in B-cells, natural killer cells and monocytes, whereas hepatocytes and mouse embryonic neurons show substantial differences. Our data set extends and statistically validates the previous observation that subunits of protein complexes tend to have coherent turnover. Moreover, analysis of different proteasome and nuclear pore complex assemblies suggests that their turnover rate is architecture dependent. These results illustrate that our approach allows investigating protein turnover and its implications in various cell types.

1 March 2018 in Cell
Verified
Journal Article
Open access
MSMikhail M. Savitski
Mikhail M. Savitski
NZNico Zinn
Nico Zinn
MFMaria Faelth-Savitski
Maria Faelth-Savitski
DPDaniel Poeckel
Daniel Poeckel
SGStephan Gade
Stephan Gade
MBMarcus Bantscheff
Marcus Bantscheff
Protein degradation plays important roles in biological processes and is tightly regulated. Further, targeted proteolysis is an emerging research tool and therapeutic strategy. However, proteome-wide technologies to investigate the causes and consequences of protein degradation in biological systems are lacking. We developed "multiplexed proteome dynamics profiling" (mPDP), a mass-spectrometry-based approach combining dynamic-SILAC labeling with isobaric mass tagging for multiplexed analysis of protein degradation and synthesis. In three proof-of-concept studies, we uncover different responses induced by the bromodomain inhibitor JQ1 versus a JQ1 proteolysis targeting chimera; we elucidate distinct modes of action of estrogen receptor modulators; and we comprehensively classify HSP90 clients based on their requirement for HSP90 constitutively or during synthesis, demonstrating that constitutive HSP90 clients have lower thermal stability than non-clients, have higher affinity for the chaperone, vary between cell types, and change upon external stimuli. These findings highlight the potential of mPDP to identify dynamically controlled degradation mechanisms in cellular systems.

1 December 2000 in RNA
Verified
Journal Article
Closed access
PDF file
GBGiovanna Bergamini
Giovanna Bergamini
Thomas PreissThomas Preiss
Thomas Preiss
MHMatthias W. Hentze
Matthias W. Hentze
In eukaryotic cells, efficient translation of most cellular mRNAs requires the synergistic interplay between the m7GpppN cap structure and the poly(A) tail during initiation. We have developed and characterized a cell-free system from human HeLa cells that recapitulates this important feature, displaying more than one order of magnitude of translational synergism between the cap structure and the poly(A) tail. The stimulation of cap-dependent translation by the poly(A) tail is length-dependent, but not mediated by changes in mRNA stability. Using this system, we investigated the effect of the poly(A) tail on the translation of picornaviral RNAs, which are naturally polyadenylated but initiate translation via internal ribosome entry sites (IRESs). We show that translation driven by the IRESs of poliovirus (PV), encephalomyocarditis virus (EMCV), and hepatitis A virus is also significantly augmented by a poly(A) tail, ranging from an approximately 3-fold stimulation for the EMCV-IRES to a more than 10-fold effect for the PV IRES. These results raise interesting questions concerning the underlying molecular mechanism(s). The cell-free system described here should prove useful in studying these questions as well as providing a general biochemical tool to examine the translation initiation pathway in a more physiological setting.